EMBC
Medical Instruments & Supplies · Healthcare
CEO, Board Member
2022-04-01–present
Board Member
Zimmer Biomet Holdings, Inc. (ZBH)Board Member
Embecta Corp. (EMBC)Equibles does not estimate personal net worth.
Get an email with a short summary when Embecta Corp. publishes a filing, an earnings call transcript or a press release.
Get EMBC alertsDevdatt Kurdikar is recorded as Board Member at Embecta Corp. (EMBC) since April 1, 2022, CEO at Embecta Corp. (EMBC) and Board Member at Zimmer Biomet Holdings, Inc. (ZBH) since January 1, 2024. The newest filing on record that lists Devdatt Kurdikar as Board Member at Zimmer Biomet Holdings, Inc. (ZBH) is dated April 1, 2026. Zimmer Biomet Holdings, Inc. reported in an 8-K filed June 20, 2024 that Devdatt Kurdikar was appointed director, effective June 20, 2024. Embecta Corp. reported in an 8-K filed April 6, 2022 that Devdatt Kurdikar was appointed director, effective March 31, 2022. Devdatt Kurdikar has spoken on 5 earnings calls across 1 company, most recently for Embecta Corp. on August 7, 2026. Embecta Corp. is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Zimmer Biomet Holdings, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Embecta Corp. includes David F. Melcher (Chairman), Devdatt (Dev) Kurdikar (Chairman), Jacob Elguicze (CFO) and 7 others.
“On June 20, 2024, the Board of Directors (the "Board") of Zimmer Biomet Holdings, Inc. (the "Company"), upon the recommendation of the Corporate Governance Committee, increased the size of the Board from ten members to eleven members and appointed Devdatt Kurdikar to fill the resulting vacancy, with a term to expire at the Company's 2025 annual meeting of shareholders.”
“Each of Devdatt Kurdikar, David F. Melcher, David J. Albritton, Carrie L. Anderson, Robert J. Hombach, Milton M. Morris, Claire Pomeroy, Karen N. Prange and Christopher R. Reidy was appointed as a director of Embecta as of immediately prior to the Effective Time”
“Before I talk about our recent acquisition of Owen Mumford, let me briefly comment on our third quarter results.”
“During fiscal year 2025, we achieved several key milestones. We made the decision to end our patch pump program and we executed a restructuring plan aimed at enhancing our profitability and free cash flow.”
“As we detailed during our recently conducted Analyst and Investor Day event, we are currently in the second phase of our journey that is focused on progressing initiatives intended to position MBECTA for long-term growth.”
“Let's start with our strategic priorities on Slide 5. We remain committed to the same trio of strategic priorities that have guided us since we established our service as an independent company.”
“And welcome, everyone, to Embecta's second quarter of fiscal year 2022 earnings call, which also marks our first quarterly earnings call as a newly public company.”
2024-01-01–present
Last confirmed April 1, 2026
2022-04-01–present
EMBC
Medical Instruments & Supplies · Healthcare
CEO, Board Member
2022-04-01–present
Medical Devices · Healthcare
Board Member
2024-01-01–present